

## Media Release

Zug, 17 June 2014

### **Result from share buy-back through the issue of put-options**

The share buy-back program launched on 22 May 2014 through the issue of put options to the shareholders has been successfully completed. Of the 8'565'400 put-options issued a total of 8'473'455 were exercised (98.93%). Thereby HBM Healthcare Investments acquired 564'897 own shares (6.35% of registered shares) in the amount of CHF 56.5 million.

At the forthcoming ordinary shareholders' meeting of 20 June 2014, the Board of Directors will propose the cancellation of those repurchased shares.

### **Shareholders benefit in several respects**

The premium over the share price enabled shareholders either to sell a tranche of their shareholding at a higher price, or to generate an additional return by selling their options. Since the announcement of the transaction on 12 Mai 2014 the share price rose by 19%, benefitting from a generally positive market and other favourable developments (announcement of excellent annual results, increase in the cash dividend payment, positive news from the portfolio companies Ophthotech and PTC). Meanwhile the net asset value (NAV) rose by 9%. Since the beginning of the calendar year 2014, the share price increased by 32% and the NAV by 20%.

As a result of the share repurchase at a price below the reported book value, the last calculated NAV of 15 June 2014 increased by a further CHF 1.05 per share (+0.9%).

For further information, please contact Dr. Andreas Wicki, tel.: +41 41 768 11 08, [andreas.wicki@hbmhealthcare.com](mailto:andreas.wicki@hbmhealthcare.com)

# NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

## HBM Healthcare Investments

### Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of some 25 promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors, and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

### Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

### HBM Healthcare Investments Ltd

Bundesplatz 1 | CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | [info@hbmhealthcare.com](mailto:info@hbmhealthcare.com)  
[www.hbmhealthcare.com](http://www.hbmhealthcare.com)